Managed Care

 

Effect of Drug Therapy on HEDIS Measurements of HbA1c Control In Diabetes Patients

MANAGED CARE February 2009. © MediMedia USA
Peer-Reviewed

Effect of Drug Therapy on HEDIS Measurements of HbA1c Control In Diabetes Patients

Gary Bazalo, MS, MBA
Managed Solutions LLC, Mount Freedom, N.J.
Richard Weiss, MS
Managed Solutions LLC, Mount Freedom, N.J.
Nathaniel Clark, MD
Senior Medical Adviser for Diabetes, Novo Nordisk Inc., Princeton, N.J.
Berhanu Alemayehu, PhD
Health Economics & Outcomes Research, Novo Nordisk Inc., Princeton, N.J.
Felicia Forma
Health Economics & Outcomes Research, Novo Nordisk Inc., Princeton, N.J.
MANAGED CARE February 2009. ©MediMedia USA

Gary Bazalo, MS, MBA

Managed Solutions LLC, Mount Freedom, N.J.

Richard Weiss, MS

Managed Solutions LLC, Mount Freedom, N.J.

Nathaniel Clark, MD

Senior Medical Adviser for Diabetes, Novo Nordisk Inc., Princeton, N.J.

Berhanu Alemayehu, PhD

Health Economics & Outcomes Research, Novo Nordisk Inc., Princeton, N.J.

Felicia Forma

Health Economics & Outcomes Research, Novo Nordisk Inc., Princeton, N.J.

Garrett Ingram ME

Health Economics & Outcomes Research, Novo Nordisk Inc., Princeton, N.J.

ABSTRACT: The purpose of this study was to corroborate an earlier study that explored the relationship between a health plan’s Health Plan Employer Data and Information Set (HEDIS) score for glycolated hemoglobin (HbA1c) control in diabetes patients and its utilization of insulin and oral diabetes products. Prescription volumes were tracked for four categories of diabetes drug therapy: analog insulin, human insulin, single-source brand oral products, and multisource generic oral products, for calendar years 2005 and 2006. The prescription shares of each of the four drug categories for each health plan were matched to the health plan’s HEDIS measurements of HbA1c control for each year. Univariate and multivariate regression analysis was performed between the health plan’s HbA1c -based HEDIS score and its prescription share of each drug category. A favorable and statistically significant (p < 0.01) relationship was found between plan HbA1c HEDIS score and plan prescription share of analog insulin in both 2005 and 2006. The correlation between HEDIS scores and human insulin was not statistically significant. Unfavorable relationships were found between HEDIS scores and both the single-source brand (statistically significant) and the multisource generic oral category prescription shares (not significant). These results corroborate the relationships found in our earlier study, although a cause and effect relationship cannot be confirmed.

Meetings

Private Health Insurance Exchanges Conference Washington, D.C. October 7–8, 2014
National Healthcare Facility Management Summit Palm Beach, FL October 16–17, 2014
National Healthcare CFO Summit Las Vegas, NV October 19–21, 2014
National Healthcare CXO Summit Las Vegas, NV October 19–21, 2014
Innovative Member Engagement Operations For Health Plans Las Vegas, NV October 20–21, 2014
4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014